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Perhaps the most
problematic, and
still largely unre-
solved, issue raised
by the HeLa story
concerns the owner-
ship of tissue once
it is removed from
the body.lthough immortality is, I guess, one of the ultimate goals of medicine, no
human has thus far achieved it, nor is anyone likely to do so for the
foreseeable future. However, the same is not true for human tissue. I
ecently read a book about Henrietta Lacks (1), the woman whose cancer provided
he HeLa cell line that has thus far proved immortal and has been responsible for
any fundamental scientific breakthroughs. Although these cells and the discoveries
hey have enabled are a cause for celebration, they have also been representative of a
umber of problematic issues in medicine, many of which remain unresolved. In
act, some of the issues may be even more prominent today as we strive to develop
tem cells and achieve tissue regeneration.
Henrietta Lacks was a poor African-American woman living in Baltimore who
eveloped a very malignant carcinoma of the cervix at a young age. The cells from
his tumor were taken, for all intents and purposes without her knowledge or con-
ent, and sent for possible tissue culture at Johns Hopkins University. They proved
o be the first “immortal” human cells capable of forever continuously reproducing
hen cultured outside of the body, enabled many medical advances, and also became
profitable commercial product. Today, HeLa cells can be found in laboratories
hroughout the world, and they continue to be the cornerstone of a large body of medi-
al research.
The first aspect of the HeLa story that struck me, as it might most clinical inves-
igators, was the serendipity of discovery. George Gey, the Hopkins researcher who
rew the cells, had been unsuccessfully trying to culture human cells for many years.
e had experimented with a myriad of culture media recipes without success. In fact,
here was nothing unique or special about the media in which he placed Henrietta
acks’ cells in comparison to that used for many other cells that did not reproduce. The
discovery” was the result of the good fortune of obtaining cells that were almost inde-
tructible. It is amazing to think of how many critical medical discoveries have depended
eavily upon chance. However, it is also true that luck leads to important discoveries
hen it encounters the prepared mind. Henrietta’s cells were absolutely unique, but
hey would have gone undetected and unrecognized had not George Gey been look-
ng and been irrepressible in his search.
A perhaps weightier issue regarding the HeLa story relates to the socioeconomic
tatus of the donor. Henrietta Lacks was a poor woman with little formal education
ho came under the clinical care of a research medical institution that provided
afety net treatment for the uninsured. Although less prevalent today, this arrange-
ent was fairly typical of the times (1950s to 1960s). So, the lower socioeconomic
lasses typically contributed disproportionately to the pool of research patients. Pa-
ients were sometimes uninformed about investigation, much less asked for their
onsent. We have long since rejected any such notions, and many of the courageous
nd altruistic patients who participate at uncertain risk in clinical trials now come
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heless, this was probably not a proud moment in medical
istory, and today there still remains a bit of a divide
n early stage research participation between patients
nd physicians in private hospitals and those in aca-
emic medical centers.
Neither Henrietta nor her family knew that her cells
ad been taken for research and were financially valu-
ble until some time after her death. The issue of in-
ormed consent has now been well addressed in the
nited States. In fact, some would say it has perhaps
one too far. Approval is now often required for activi-
ies that could not constitute either risk or financial
enefit to the patient. Nevertheless, it is probably bet-
er to do too much than too little. It is startling, how-
ver, to see the change in attitudes in the last several
ecades, and to realize that only a short time ago re-
earch was performed without the knowledge or under-
tanding of the subjects.
Perhaps the most problematic, and still largely unre-
olved, issue raised by the HeLa story concerns the
wnership of tissue once it is removed from the body.
elling Henrietta’s cells ultimately provided a profitable
usiness opportunity although Dr. Gey and Hopkins
ave the cells away for free. However, neither Henri-
tta nor any of her relatives have ever received a penny
f income. Among the questions raised is whether an
ndividual has to be informed that tissue removed from
is or her body may be used for research and has to
onsent to this use; the answer is apparently no. I must
dmit, I have had blood drawn for tests many times,
ut I have never wondered where the specimen has
one, and certainly never considered that it might be
sed for research. But, it appears that is entirely possi-
le; we legally lose all ownership of our body parts
henever they are removed from the whole. The ancil-
ary issue is who should benefit if the tissue leads to a
rofitable commercial business. At the moment, the
nswer seems to be that the patient has neither a right
or recourse to any financial gain from the tissue that
e or she provided for the research.
The above issues of informed consent and financial
ain are controversial and are the subjects of consider-
ble ongoing debate. As a patient, I instinctively feel
hat, if it is my body, I should own the part, should
ertainly be informed if and how it will be used, and
hould share in any financial gain. This certainly seems
o be true for all of our other worldly possessions. Al-
hough it is logical that we have a strong responsibility
o do what is best for society with our tissue, this does tot apply to other possessions such as money or prop-
rty. Those opposed to this concept (not surprisingly,
rimarily the scientific and medical industry commu-
ity) contend that the general rules governing the con-
uct of clinical research already provide adequate pro-
ection for the rights of patients regarding their tissues.
mportantly, they argue that our moral obligation to
enefit society outweighs personal considerations, and
hat good health differs from other possessions in this
egard. They point out the logistical difficulties in try-
ng to give patients control of their tissues. The actual
nvestigation the specimen is used for may occur many
ears after and for a problem unforeseen at the time of
onation. Finally, those opposed to patient control
orry that the potential of a financial benefit may lead
o unrealistic demands and negotiations and, eventu-
lly, to the loss of important opportunities for medical
dvances. Of course, this applies equally well to the
ntellectual property rights that the scientific commu-
ity values and utilizes.
While the issues relating to the control of removed
iological material have always existed, they may be
ven more pressing in the future. Cardiac regeneration
tilizing stem cells is one of the major thrusts of con-
emporary research. We have participated in several
tudies in which the evidence of immune protection of
tem cells has been exploited to utilize donor cells for
herapy. Prior to reading Skloot’s book (1), I would not
ave thought to question the consent of the donors or
heir participation in any profits. In addition, the revolu-
ion in genetics/genomics has raised questions regarding
he ownership of genes and genetic material. It seems
lear that these questions will receive more rather than
ess attention as time goes by.
Rebecca Skloot has written a magnificent book (1),
nd one which raises important questions for us in
edicine to address. We are walked through the seren-
ipitous discovery of “immortal” cells at Hopkins, and
e wonder how many other similar tissues were dis-
arded due to the lack of interest of those in charge.
s the saying goes, those who work the hardest often
ave the most luck. We are once again reminded of the
rucial importance of our patients to our research; they
re the real heroes. As for the ownership of biological
aterial removed from the body, I am ambivalent. It
eems absolutely reasonable that patients should have a
ay in whether and how their tissues might be used,
nd share in any profits that might result. While it
ight be an unearned gift to have tissue of great value,he same could be said for great intelligence, or a great
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f a tissue had the potential to provide a cure for can-
er, I cannot see how the rights of the patient could
utweigh the potential benefit to society. We have
iven government the right of eminent domain to ac-
uire real estate, so surely we could do the same for
iological material. As in all things in medicine, we as
hysicians should take the lead in resolving these di-
emmas. Although immortality remains an elusive and
resumably extremely desirable goal, it is clearly not
ithout its problems.
1ddress correspondence to:
r. Anthony N. DeMaria
ditor-in-Chief, Journal of the American College of Cardiology
655 Nobel Drive, Suite 630
an Diego, California 92112
-mail: ademaria@acc.org
EFERENCE. Skloot R. The Immortal Life of Henrietta Lacks. New York, NY:
Crown Publishers, 2010.
